-+ 0.00%
-+ 0.00%
-+ 0.00%

Contineum Q1 FY26 net loss narrows 9.6% to $14.5 million

PUBT·05/05/2026 20:19:32
Listen to the news
Contineum Q1 FY26 net loss narrows 9.6% to $14.5 million
  • Contineum Therapeutics reported a net loss of USD 14.5 million, narrowing from USD 16 million, or USD 0.39 per share versus USD 0.62 per share.
  • Research and development expense fell 15% to USD 11.6 million, while general and administrative costs rose 20% to USD 5.3 million.
  • Cash, cash equivalents and marketable securities totaled USD 246.3 million, with cash runway projected through mid-2029.
  • Positive topline data were reported from an exploratory Phase 1b chronic pain trial of PIPE-791, while dosing began in the PROPEL-IPF global Phase 2 study in first quarter 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Contineum Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202605051605BIZWIRE_USPR_____20260505_BW645392) on May 05, 2026, and is solely responsible for the information contained therein.